(anti-HCV) positive. 4 Studies from Europe, Australia and the United
States suggest that the prevalence of anti-HCV in prison populations may be higher still, ranging from 8% to 57%. 4, 5 In the last few years, there has been a substantial improvement in the efficacy and tolerability of HCV treatments, with the development of direct-acting antivirals (DAAs). [6] [7] [8] Now more than 95%
of those treated with an 8-to 12-week oral combination of DAAs achieve a sustained virological response (SVR), defined as HCV RNA not detected 3-month post-treatment, which is accepted as indicating a cure of the infection. 9 SVR has also been shown to significantly reduce the risk of liver-related complications, hepatocellular carcinoma, and both liver-related and all-cause mortality. 10, 11 These dramatic improvements in antiviral therapy present a major public health opportunity, and in 2016 Public Health England 1 agreed to support the World Health Organization strategy to eliminate HCV as a major public health threat by 2030. 12 The WHO goal for incidence reduction is 80% for HCV, 95% for HBV and 90% for HBV and HCV combined. 12 Given the high prevalence of HCV in prison populations, any programme designed to achieve elimination needs to significantly increase the diagnosis and treatment of HCV in prisons. In England, however, testing rates in prisons have historically been low (c. 4%),
with inconsistent approaches across the health and justice systems. 13 In 2013-2014, for example, in one of the prisons in North East
England (NEE) only 8% of prisoners were tested for HCV, with 43%
of these being HCV antibody positive. 14 At that time, HCV testing was conducted by the sexual health team on individuals specifically referred for HCV testing from other services (drug and alcohol inreach, mental health or primary care) within the prison. Attendance rates at these testing appointments were low, while the high positivity rate suggested a high burden of undiagnosed infection.
In response to the low rates of HCV testing in UK prisons, in 2013 PHE, NHS England (NHSE) and the National Offender Management Service (NOMS) published a Joint Partnership Agreement. This partnership recommended that all prisoners should receive a universal offer of blood borne virus testing (UOBBVT) at or near to reception into prison. In 2014, the NEE "UOBBVT task and finish" group began developing a programme to implement UOBBVT in all NEE Prisons.
In addition, a robust HCV treatment pathway was developed to effectively deliver antiviral treatment within the prisons. 14 This pathway included consultant-led telemedicine clinics (TC) supported by specialist nurse in-reach.
Here, we present the results of the 1-year pilot of UOBBVT in Her Majesty's Prison (HMP) Durham and the pilot of TC HCV treatment clinics in HMP Northumberland.
| ME THODS

| Development of the blood borne virus testing and treatment pathway
In 2014, the "task and finish" team was convened to develop a blood borne virus testing (BBVT) and treatment pathway for all the prisons in NEE. This team was comprised of public health consultants, prison healthcare staff, commissioners, viral hepatitis specialist consultants and viral hepatitis specialist nurses.
The overall initial aims of the group were to optimize blood borne virus (BBV) testing rates within the NEE HMP estate and to expand BBVT opportunities within the whole prison environment. To achieve these aims, an adequately funded UOBBVT programme at reception to prison has been developed, feeding into robust treatment pathways. The HCV treatment pathway is designed to ensure a high proportion of HCV RNA-positive individuals are able to commence and complete treatment, either within the prison establishment or in the community if the prisoner is released prior to commencing treatment.
To inform the development of this new service, an audit of HCV testing and treatment rates in the NEE prisons was conducted in 2013/4
to determine baseline activity. To secure adequate funding, economic models were developed to assess the fiscal impact of UOBBVT and the introduction of consultant telemedicine HCV clinics. 
| The prison estate in the North East of England
The prison estate in NEE comprises seven facilities. This project was piloted in HMP Durham, a large category B male remand prison taking approximately 7000 receptions awaiting trial annually and HMP Northumberland, a large category C male prison with a fairly stable population of 1354 inmates.
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The initial pilot of UOBBVT was conducted at HMP Durham before being rolled out in a staged manner to other HMPs across the NEE estate. The pilot of consultant-led telemedicine HCV clinics was conducted at HMP Northumberland and was also rolled out across the prison estate.
| The BBV testing pathway
Prior to the implementation of the new BBV testing pathway, it was routine practice to use standard venepuncture to test for BBV in the prisons. This method, however, was unpopular with prisoners, and some of the individuals most at risk of HCV were difficult to obtain blood from due to a previous history of injecting drug use.
Therefore, in order to maximize uptake of BBVT, dry blood spot test- available at all times to perform the blood testing. Staff were encouraged to be positive when seeking consent from prisoners and to indicate that is was routine practice for all inmates to be tested for BBVs.
Dry blood spot (DBS) samples, along with venous blood samples, were sent to the regional Public Health Laboratory for testing.
| DBS testing
Dry blood spot samples were tested for HCV, HBV and HIV using Roche Elecsys® Anti-HCV II, Elecsys® HIV combi PT and Elecsys® HBsAg II assays on a Cobas® 8100 platform as previously described. 16, 17 Dry blood spot samples which were anti-HCV positive results
were confirmed using HCV RNA on DBS samples. Any prisoners who were confirmed as being HCV RNA positive were referred for treatment. In these consultations, detailed counselling advised them about opportunities for treatment and risk reduction.
For those with a anti-HCV positive, but negative HCV RNA by DBS repeat HCV testing with standard venous blood was undertaken to confirm the DBS result in order to rule out false-positive antibody result and false-negative RNA result.
| BBV testing rates from HMP Durham before and after implementation of the new testing pathway
Baseline BBV testing rates (prior to the initiation of the new BBV testing pathway) at HMP Durham (and all other prisons across NEE)
were previously assessed for 2013/4 and reported by PHE. 18 These baseline testing rates were used as a comparator to assess the impact of the new UOBBVT.
Following the implementation of the UOBBVT, data were collected prospectively. These included the number of new receptions who were offered DBST, the number who declined testing, the number who tested anti-HCV positive and the number who were HCV RNA positive. In addition, data were collected on the total number of BBV tests conducted anywhere in the prison.
| New HCV treatment pathway
Prior to the implementation of TC in HMP Northumberland, HCVpositive inmates were reviewed in the HCV clinic at the Freeman Hospital, Newcastle, with a maximum of one inmate per week.
Attendance rates were poor, costs for prisoner transport were high and few patients ever started treatment. The new treatment pathway using consultant-led TC with viral hepatitis nurseled prison in-reach clinics was designed to optimize the treatment pathway, thus increasing efficiency and treatment rates. 19 This was fully implemented at HMP Northumberland in August 2015. HMP
Northumberland houses a more stable prison population than other facilities within the NEE prison estate, with many inmates undertaking medium lengths of sentence. It was therefore felt to be an ideal prison to test the treatment pathway, as the majority of prisoners would be able to complete treatment while in custody.
All individuals found to be HCV RNA positive were offered an assessment for treatment with the in-reach viral hepatitis nurse (weekly clinic) similar to a model described previously in Australian Prisons. 19 At this initial consultation, the nurse obtained an inmate history and conducted a physical examination, pre-treatment blood tests, liver ultrasound and transient elastography. Once the results of these tests were available, a second consultation was conducted via TC video link with the hepatology consultant (TCs being delivered fortnightly or monthly depending on demand) and a decision was made whether or not to proceed with treatment. All patients were then discussed in the regional Repeat sample taken for confirmaƟon. Linked to specialist care.
5-7 days 7 days
hepatitis C multidisciplinary meeting and commenced on a combination of DAAs in line with NHS England recommendations, if appropriate.
All HCV RNA-positive individuals with a short sentence that precluded commencement of antiviral therapy in prison were provided with written information about their diagnosis, given details of contacts for community HCV treatment services, and encouraged to access treatment upon release from prison.
| Review of treatment rates prior to and after implementation of the telemedicine treatment pathway in HMP Northumberland
A retrospective audit of HCV treatment was conducted in HMP Northumberland in 2013/4 and formed part of the PHE report in 2014. 18 This provided baseline data on treatment rates for comparison with the new treatment pathway. Following introduction of the prison HCV TC, data were collected prospectively on HCV RNA positive referral rates, attendance rates and antiviral treatment rates.
Patients accessing the clinic were also invited to complete a short satisfaction questionnaire.
| RE SULTS
| A universal offer of BBV testing increases testing rates in HMP Durham
The Common reasons for non-acceptance of the test were inmates stating: "does not want it" (54%), "already had test" (37%) or "does not need it" (5.4%) as illustrated in Figure 3. 3.2 | What was the outcome for the HCV RNApositive individuals? Table 1 Since the introduction of the BBV testing programme, treatment rates have dramatically increased across the NEE prison estate.
| Rollout of UOBBVT to the other NEE prisons
Between February 2017 and January 2018, a total of 159 commenced antiviral treatment, as shown in Table 2 . This is in part due to the increased testing rates in Durham as many prisoners who test positive for HCV are transferred to other prisons in NEE where they receive treatment. increased 10-fold and there has been a notable reduction in clinic non-attendance rates from 50% to 17%.
| D ISCUSS I ON
The prevalence of anti-HCV positivity in HMP Durham was similar to other UK prisons (6.4% vs 7%). However, this is significantly lower than is seen in other countries, such as Australia, where the prevalence rate is between 23% and 33%. 20 The reasons for the significant differences is not clear, but could be due to the difference in HCV prevalence in the general population, which is known to be higher in Australia than England (0.9% vs 0.3%). In addition, there could be differences in the proportion the prison population who are current or previous injecting drug users or the rate of HCV in injecting drug users between the countries. Moreover, harm reduction methods may differ. It is interesting to note that only 49.5% of the individuals testing anti-HCV positive were viraemic, which was lower than has been seen in other settings. This is thought to be unlikely to be due to patients receiving treatment previously as very few had Although there has been a large increase in testing rates among prisoners at first reception, overall rates of uptake of BBV testing remain suboptimal at 35%. In order for a BBV testing programme to be truly "universal opt-out", and consequently highly effective, offer and acceptance rates need to be >90%, and further work is needed to optimize testing. The major reasons for non-acceptance of the test were "does not want it" (54%) and "already had test" (37%).
Reasons why those who did not want the test needs further exploration. It may be that reception to prison is not the best time to offer individuals BBV testing as this may be a stressful time for the new receptions. In addition, reception can be busy (>7000 receptions/y in HMP Durham), making it difficult to find time to encourage waverers to take the test. A significant number of receptions said they had "already had the test". In this pilot, we were unable to verify if this was the case, but further work is needed to understand the validity of such a claim. Robust mechanisms need to be in place to access previous BBV test results, if available, to verify whether inmates have been tested and to reduce duplicate testing. Use of a common computer system, with access to electronic health records, across the whole UK prison estate will reduce the risk of duplicate testing.
Previous studies have identified a number of barriers to BBV testing in the incarcerated population. 21 These include important organizational issues such as lack of a structured approach to testing, long waiting times, poor linkage to care for those with a positive test, limited knowledge about HCV by prison staff and differing health priorities. 21, 22 Our work has overcome many of these barriers.
In addition, there are a number of personal barriers to testing such as concerns about stigma and confidentiality, low motivation for testing in some individuals, 21 lack of understanding around the perceived risk of BBV, lack of understanding of the consequences of untreated HCV, and lack of knowledge that it can be relatively easily treated with DAAs. 23 Our systematic approach to staff training about HCV and other BBVs has also helped address some of these barriers, but
clearly there is more work to do to further increase testing rates.
Staff have now routinely embedded BBV testing in reception to normalize it. However, there is a regular turnover staff in the prison so an ongoing process of education is essential to maintain a high testing rate. Although we have not explored the use of incentives for prisoners having a test or staff undertaking the test, this might be a way to increase testing rates further and is worthy of a trial. which is more acceptable than standard venepuncture that is still used in many UK prisons. DBST increases the likelihood of individuals accepting a test by threefold to sixfold compared with standard venepuncture. 24, 25 This technique is also not dependent on the need for specialist skills in venepuncture, resulting in many more staff being able to perform the test. [26] [27] [28] DBST has very good sensitivity (>96%) and specificity (>98%) for HCV 29 and has been shown to be a cost-effective screening tool for HCV within the prison setting, 26 making it a good testing system in prisons. [28] [29] [30] In addition to developing the UOBBVT, we introduced a new treatment pathway to help deal with the expected increase in patients diagnosed with HCV and to ensure high rates of treatment.
This involved the introduction of specialist nurse in-reach clinics with consultant-led TC, which significantly increased the number of patients treated in HMP Northumberland. The pathway was also very efficient in reducing the need for prisoner transport, which cost £250-500 per hospital visit. The telemedicine approach was also an efficient use of consultant time, allowing the consultant to do the clinic from their hospital base where other activities are ongoing.
Following the successful introduction of the TC in Northumberland
Prison, this pathway is now used in other prisons in NEE. In the last year, 159 patients were commenced on antiviral treatment across the whole estate, which represents a large increase in treatment rates (54 in previous year). Clearly, not all of the increase in activity is due to the new treatment pathway. Availability of the new DAAs is also likely to have contributed as more patients are willing to undergo treatment with DAAs than with interferon-based treatments, which were poorly tolerated and had modest HCV clearance rates. 6, 8, 31 One of the key success factors of a BBV testing programme is to ensure that all BBV positive cases are linked into treatment. The pilot work of HCV testing in Durham Prison showed that linkage to treatment for those testing positive for HCV was low (~20%).
The likely explanation for this is that HMP Durham is now entirely a remand prison and, as a result, many inmates have a very short prison stay. It is also hard to predict how long inmates will be in the prison as they are awaiting court appearances and sentencing. 
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